MariMed (MRMD) versus The Competition Head to Head Analysis

MariMed (OTC:MRMD) is one of 55 public companies in the “Medicinals & botanicals” industry, but how does it contrast to its peers? We will compare MariMed to similar businesses based on the strength of its earnings, dividends, profitability, risk, analyst recommendations, valuation and institutional ownership.

Risk and Volatility

MariMed has a beta of 3.15, indicating that its share price is 215% more volatile than the S&P 500. Comparatively, MariMed’s peers have a beta of 1.30, indicating that their average share price is 30% more volatile than the S&P 500.

Insider and Institutional Ownership

0.2% of MariMed shares are owned by institutional investors. Comparatively, 15.8% of shares of all “Medicinals & botanicals” companies are owned by institutional investors. 19.0% of MariMed shares are owned by insiders. Comparatively, 21.5% of shares of all “Medicinals & botanicals” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares MariMed and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MariMed	-8.95%	1.58%	0.53%
MariMed Competitors	-38.94%	-24.68%	-6.33%

Analyst Recommendations

This is a summary of recent ratings and price targets for MariMed and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MariMed	0	0	0	1	4.00
MariMed Competitors	289	566	1084	86	2.48

As a group, “Medicinals & botanicals” companies have a potential upside of 80.15%. Given MariMed’s peers higher possible upside, analysts plainly believe MariMed has less favorable growth aspects than its peers.

Valuation & Earnings

This table compares MariMed and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
MariMed	$148.60 million	-$16.03 million	-2.47
MariMed Competitors	$310.32 million	-$49.81 million	-5.48

MariMed’s peers have higher revenue, but lower earnings than MariMed. MariMed is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Summary

MariMed beats its peers on 8 of the 13 factors compared.

About MariMed

MariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company sells flowers and concentrates under the Nature’s Heritage brand; and soft and chewy baked goods and a hot chocolate mix under Bubby’s Baked brand; and drink mix under Vibations brand. It also offers chewable cannabis-infused mint tablet under the brand Kalm Fusion; and flower, vapes, and edibles under InHouse brand. In addition, the company provides supplement, nutrient-infused fruit chews under Betty’s Eddies brand and ice creams under Emack & Bolio’s brand. The company licenses its brands. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts.